Coronary Artery Bypass Graft News and Research RSS Feed - Coronary Artery Bypass Graft News and Research

Statins reduce risk of death by 67% in CABG surgery

Statins reduce risk of death by 67% in CABG surgery

Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine. [More]
FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic. [More]
Research: Reducing emergency surgery for common procedures could cut health care costs

Research: Reducing emergency surgery for common procedures could cut health care costs

New research indicates that reducing emergency surgery for three common procedures by 10 percent could cut $1 billion in health care costs over 10 years. [More]
Baylor Scott & White Health forms alliance with Cleveland Clinic

Baylor Scott & White Health forms alliance with Cleveland Clinic

Baylor Scott & White Health today announces an alliance with Cleveland Clinic's Sydell and Arnold Miller Family Heart & Vascular Institute. [More]
Study: Preoperative interventions improve outcomes of patients undergoing CABG surgery

Study: Preoperative interventions improve outcomes of patients undergoing CABG surgery

A quality improvement initiative improved the outcomes of patients undergoing cardiac surgery at select medical centers in northern New England, according to a study in the December issue of Critical Care Nurse (CCN). [More]
Preoperative IV ibuprofen improves quality of recovery after laparoscopic cholecystectomy surgery

Preoperative IV ibuprofen improves quality of recovery after laparoscopic cholecystectomy surgery

Cumberland Pharmaceuticals Inc. today announced that preoperative intravenous ibuprofen improved overall quality of recovery in patients undergoing laparoscopic cholecystectomy surgery. These results will be presented at the American Anesthesiology 2014 Annual Meeting in New Orleans, Louisiana. [More]
Surgical patient safety program significantly reduces cardiac surgical site infections

Surgical patient safety program significantly reduces cardiac surgical site infections

A common postoperative complication after open heart operations-infection at the surgical site-has been reduced by 77 percent at a Canadian hospital through its participation in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP-), according to a new case study presented at the 2014 ACS NSQIP National Conference. [More]
Cumberland launches new Vaprisol product

Cumberland launches new Vaprisol product

Cumberland Pharmaceuticals Inc. today announced the launch of its active promotional campaign to support its new Vaprisol® product. [More]
Study: Repeat sternotomy for surgical aortic valve replacement safe for octogenarian patients

Study: Repeat sternotomy for surgical aortic valve replacement safe for octogenarian patients

Surgical aortic valve replacement generally improves patients' symptoms and prolongs survival. However, the perceived risk of surgical aortic valve replacement in patients over 80 may result in surgery being denied or a recommendation for alternative therapy. Investigators at the Mayo Clinic challenge the way these patients have been managed. [More]
FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults. [More]
Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees. [More]
FDA approves New Drug Application for PENNSA 2%

FDA approves New Drug Application for PENNSA 2%

Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s). [More]
FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults. [More]
Aortic valve replacement improves survival and outcomes in elderly patients

Aortic valve replacement improves survival and outcomes in elderly patients

Jose Augusto Barreto-Filho, M.D., Ph.D., of the Federal University of Sergipe and the Clinica e Hospital Sao Lucas, Sergipe, Brazil, and colleagues assessed procedure rates and outcomes of surgical aortic valve replacement (AVR) among 82,755,924 Medicare fee-for-service beneficiaries between 1999 and 2011. [More]
Study reveals substantial economic impact of HAIs following cardiac surgery

Study reveals substantial economic impact of HAIs following cardiac surgery

After cardiac surgery, healthcare-associated infections (HAIs) are common complications associated with increased morbidity, mortality, and use of resources. [More]
Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results. [More]
FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products. [More]
Advertisement
Advertisement